



Zealand announces total number of shares and voting rights in the company as of 30 September 2015

Copenhagen, 30 September 2015 - In accordance with Section 6 of the *Danish Statutory Order on Issuers' Disclosure Obligations*, Zealand announces the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.

With reference to Company Announcement no. 38/2015 dated 8 September 2015 and Company Announcement no.42/2015 dated 26 September 2015, the table below provides the total number of shares and voting rights in Zealand as of 30 September 2015.

| | Number of shares (nominal value DKK 1) | Nominal value in DKK | Number of votes |
|--------|---|-------------------------|-----------------|
| Shares | 24,052,000 | 24,052,000 | 24,052,000 |



For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a medicinal biotech company with leading expertise in the identification, design and development of novel peptide medicines. Zealand has a proprietary pipeline of novel drug candidates and a portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim – primarily in the fields of cardio-metabolic diseases and acute care indications.

The proprietary pipeline includes; *danegaptide* for ischemic reperfusion Injuries in Phase II development, *ZP1848* for Short Bowel Syndrome in Phase II development and the stable glucagon analogue, *ZP4207* as a *single-dose rescue pen* for severe hypoglycemia in preparation for Phase II, and *ZP4207* as *multiple-dose use* for the correction of mild to moderate hypoglycemia in evaluation for the next clinical development step after Phase I, as well as *several preclinical peptide therapeutics*.

Zealand has invented lixisenatide, a once-daily prandial GLP-1 agonist, which is marketed globally (ex-US) by Sanofi for the treatment of Type 2 diabetes and since end September 2015 has been under review by the FDA in the US. The license agreement with Sanofi also covers a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in Q4 2015 and in Europe in Q1 2016.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma